Please assess the completion status of the following clinical trial:

Trial Title: Sudden Deafness Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men/women 18 years and older in good health~* Unilateral sensorineural hearing loss developing within 72 hours (SSNHL)~* Pure Tone Average (PTA) (500, 1000, 2000, 4000 Hz) \>/= 50 dB in the affected ear, with the affected ear \>/= 30 dB worse than contralateral ear in at least one of the four frequencies~* Symmetric hearing prior to onset of SSNHL~* Hearing loss must be idiopathic~* Hearing loss must have occurred within the past 14 days~* Must be able to read or write English or Spanish~Exclusion Criteria:~SYSTEMIC DISEASE~* \>21 days prior oral steroid treatment within preceding 30 days~* History of tuberculosis (TB) or positive PPD~* Insulin-dependent diabetes mellitus~* History of rheumatic disease, e.g., rheumatoid arthritis, scleroderma, lupus, etc.~* Serious psychiatric disease or psychiatric reaction to corticosteroids~* History of heart disease or transient ischemic attacks (TIAs)~* Prior treatment with chemotherapeutic or immunosuppressive drugs~* Pancreatitis~* Active peptic ulcer disease or history of gastrointestinal bleeding~* History of HIV, Hepatitis B or C~* Chronic kidney failure~* Alcohol abuse~* Active shingles~* Severe osteoporosis or non-surgical aseptic necrosis of the hip~OTOLOGIC DISEASE~* Prior history of SSNHL~* History of fluctuating hearing loss~* History of Meniere's disease~* History of chronic ear infection~* History of otosclerosis~* History of ear surgery (except childhood pressure equalization \[pe\] tubes)~* History of congenital hearing loss~* History of trauma immediately preceding onset of SSNHL~* History of syphilitic hearing loss~* History of genetic/hereditary hearing loss~* Skull, facial, or temporal bone anomalies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Nineteen days of oral prednisone
- 2 (Type: EXPERIMENTAL): Four doses of methylprednisolone sodium succinate delivered by injection to the middle ear over 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).